Skip to main navigation
In order to offer and provide a customized and personal service through our products and websites, we may use cookies to store and help track information about you. ×
Logo

PIONEERING IMMUNOTHERAPY

SEC Filings

SEC Filing Keyword Search

Filing date Form Description Filing Group View
March 19, 2019 CT ORDER

CT ORDER

Other
9999999997-19-001432.rtf
View HTML
9999999997-19-001432.pdf
February 27, 2019 424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Registration Statements
0001193125-19-054130.rtf
View HTML
0001193125-19-054130.pdf
0001193125-19-054130.xls
February 27, 2019 8-K

Report of unscheduled material events or corporate event

Current Reports
0001564590-19-004945.rtf
View HTML
0001564590-19-004945.pdf
0001564590-19-004945.xls
February 27, 2019 S-8

Securities offered to employees pursuant to employee benefit plans

Registration Statements
0001193125-19-054155.rtf
View HTML
0001193125-19-054155.pdf
0001193125-19-054155.xls
February 27, 2019 10-K

Annual report which provides a comprehensive overview of the company for the past year

Annual Filings
0001564590-19-004942.rtf
View HTML
0001564590-19-004942.pdf
0001564590-19-004942.xls
EX-101.INS - XBRL INSTANCE DOCUMENT
February 27, 2019 4

Statement of changes in beneficial ownership of securities

3,4,5
0001567619-19-005538.rtf
View HTML
0001567619-19-005538.pdf
February 21, 2019 8-K

Report of unscheduled material events or corporate event

Current Reports
0001193125-19-046243.rtf
View HTML
0001193125-19-046243.pdf
0001193125-19-046243.xls
February 21, 2019 3

Initial filing by director officer or owner of more than ten percent.

3,4,5
0001567619-19-005094.rtf
View HTML
0001567619-19-005094.pdf
0001567619-19-005094.xls
February 21, 2019 4

Statement of changes in beneficial ownership of securities

3,4,5
0001567619-19-005097.rtf
View HTML
0001567619-19-005097.pdf
February 21, 2019 4

Statement of changes in beneficial ownership of securities

3,4,5
0001567619-19-005101.rtf
View HTML
0001567619-19-005101.pdf

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »

In This Section

  • SEC Filings
  • Annual Reports

Investor Toolkit

  • Print Page
  • RSS Feeds
  • Email Alerts

Investor Relations

  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Analyst Coverage
  • Stock Information
  • FAQs
  • Home
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Headquarters
    • Community Affairs
  • Pipeline
    • Clinical Trials
    • Access to Our Investigational Agents
  • Technology
    • Immunotherapy
    • STING Pathway
    • APRIL Pathway
    • Scientific Publications
    • Intellectual Property
  • Partnerships
  • Media
    • Press Releases
  • Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Analyst Coverage
    • Stock Information
    • FAQs
  • Careers
  • Contact
  • Home
  • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Global Headquarters
    • Community Affairs
  • Pipeline
    • Clinical Trials
    • Access to Our Investigational Agents
  • Technology
    • Immunotherapy
    • STING Pathway
    • APRIL Pathway
    • Scientific Publications
    • Intellectual Property
  • Partnerships
  • Media
    • Press Releases
  • Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Analyst Coverage
    • Stock Information
    • FAQs
  • Careers
  • Contact
  • Privacy Policy
  • Terms and Conditions of Use
Logo© 2019 Aduro BiotechAll rights reserved
  • Privacy Policy
  • Terms and Conditions of Use
Website Design: Hane Chow, Inc.
TwitterLinkedIn